BCL2 and leukemia: Most importantly, also in this cohort we found that functional BCL-2 dependence of the leukemia cells measured by BAD-HRK priming is significantly associated with preclinical response (Fig. 4b) predicting in vivo antileukemia VEN activity, in both BCP- and T-ALL (Fig. 4c).